EUVIMEDEUVIMED entdecken
Crossref

Frailty scoring in the management of people with skin cancer: a critically appraised topic

Anna M Hughes iD, James Powell, Rachel A Abbott

Clinical and Experimental Dermatology · 08.09.2026

DOI: 10.1093/ced/llag388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 08.09.2026. Verfasst von Anna M Hughes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Swansea Bay University Health Board, Swansea, UK. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin cancer incidence is rising in the UK, and with an increasingly ageing population, so is frailty. Frailty scoring is not routinely used in skin cancer multidisciplinary team (MDT) decisions but may have the potential to enhance and personalize clinical management. The aim of this narrative review was to evaluate the literature on clinical tools used to assess frailty, guide management of people with skin cancer (melanoma and keratinocyte cancer) and identify the best frailty score to be used in skin cancer MDT management decisions in the UK. A literature search was conducted using PubMed and Embase and the results were screened for relevance to the clinical question. From the literature, we identified 12 different scoring tools studied in the management of skin cancer, across 15 papers, which we subcategorized into ‘comorbidity’ and ‘frailty’ assessment tools. Of these, the Geriatric-8, Charlson Comorbidity Index and Adult Comorbidity Evaluation-27 were determined to be the most effective at identifying and stratifying frailty. However, the Rockwood Clinical Frailty Score is currently recommended by the British Geriatrics Society and British Association of Dermatologists. Notwithstanding the limitations of this critical appraisal (small cohort sizes, single-centre biases and overlapping or similar patient populations) we conclude that frailty scoring should be used in skin cancer MDTs so that patient-related factors and tumour-related factors are considered when managing skin cancer in older patients. Frailty scoring helps identify patients with limited life expectancy and greater risk of complications, who may not benefit from ‘gold-standard’ treatments.

Autor:innen und Institutionen

  • Swansea Bay University Health Board, Swansea, UK.
  • Cardiff University, Cardiff, UK.
  • Wye Valley NHS Trust, Hereford, UK.
  • Cardiff and Vale University Health Board, Cardiff, UK.

ORCID-Profile: Anna M Hughes

Zitieren

APA

Hughes, A. M., Powell, J., & Abbott, R. A. (2026). Frailty scoring in the management of people with skin cancer: a critically appraised topic. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag388

Vancouver

Hughes AM, Powell J, Abbott RA. Frailty scoring in the management of people with skin cancer: a critically appraised topic. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag388

BibTeX
@article{Hughes2026,
  author = {Hughes, Anna M and Powell, James and Abbott, Rachel A},
  title = {Frailty scoring in the management of people with skin cancer: a critically appraised topic},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag388}
}
Kostenlos starten →